Tuesday, April 6th, 2021 - ENT Technologies

 

ENT Technologies is eagerly awaiting results from additional clinical trials, based on using its carrageenan-saline nasal spray to demonstrate preventative action against the COVID-19 virus. These clinical trials have progressed based on successful laboratory findings of the carrageenan-saline spray in Austria1,2 and the United States of America,3. It is anticipated that the action of this carrageenan saline nasal spray, in conjunction with a well-fitted face mask, may provide an effective prevention regimen against COVID-19.

ENT Technologies is a Melbourne-based Pharma company specialising in the development and marketing of products that help manage various nasal and sinus conditions. ENT’s carrageenan-saline nasal spray is currently registered for use and available in most retail pharmacies in Australia as a protective moisture barrier for hydrating and soothing nasal mucosa. It may also be used to temporarily relieve the severity and shorten the duration of symptoms of common colds.

Carrageenan’s observed mode of action has been shown to bind to the lining of nasal tissue to help trap viruses responsible for the common cold and so prevent them from entering the tissue cells where they would otherwise give rise to the infection1 .

In the laboratory

Carrageenan, derived from red seaweed, has been shown to block two of the most common cold-causing viruses, namely Rhinovirus strains and Coronavirus (type OC 43)2 . Tolerability studies have shown no adverse effects on either the structure or the functioning of delicate nasal tissues. The carrageenan molecule is large and does not enter into the body’s circulation. It can be used in adults and children from 2 years of age.

Clinically

Several studies have shown, when carrageenan-saline nasal spray is used within 48 hours of the start of cold symptoms, it helps to shorten the duration and reduce the symptoms of colds. It has also been shown to reduce the relapse rate from these colds by up to 60%2 .

- END -

References: 1. Iota Carrageenan neutralises SARS-CoV-2 and inhibits viral replication in vitro. Morokutti-Kurz M et al. PLOS ONE 16(2) e 0237480 17th February 2021 https://doi.org/10.1371/journal.pone.0237480 2. Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: re-analysis of randomized trial data. Hemila H and Chalker E. DOI: https://doi.org/10.21203/rs.3.rs-108775/v1 3. Carrageenan containing over the counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures Schutz D et al. American Journal of Physiology and Lung Cellular and Molecular Physiology February 9th 2021 https://doi.org/10.1152/ajplung.00552.2020

For Media Enquiries

Dr Sam Barbalatt (Medical Director) or Deborah Clemens (Marketing Manager)

ENT Technologies Pty Ltd, Suite 304, 12 Cato Street, Hawthorn East, VIC 3123

Tel: (03) 9832 3700  or 0403 447 681  Email: [email protected] 

Web: www.enttech.com.au 

Contact Profile

ENT Technologies


Since 2003, ENT Technologies Pty Ltd has led the way by providing the most innovative nasal sprays and sinus washes in the Australian marketplace. ENT are considered experts in the field and are committed to the latest advancements and technologies in developing effective formulations and easy delivery systems for managing a range of common nasal and sinus problems such as sinusitis, hay fever, blocked nose, runny nose, colds and more.

ENT Technologies is a proud supporter of  Asthma Australia and Asthma WA and the Victorian Pharmacy Students’ Association

As makers of a full range of preservative-free nasal sprays and washes, ENT Technologies' products can make a difference especially for people managing a range of common respiratory conditions including upper respiratory tract infections and allergic rhinitis (hay fever).


Deborah Clemens
P: +61398323700
M: 0403 447681
W: www.enttech.com.au

Keywords

nasal spray, COVID-19, respiratory health, clinical trials, carrageenan, red seaweed, cold infection, viral infection, respiratory tract infection, corona virus, rhinovirus, common cold, over the counter, Melbourne, Australian company, pharmaceuticals

Categories

Sharing

More Formats